奥浦迈跌5.9% 2022年上市募16亿正拟14.5亿收购

Core Viewpoint - Aopu Mai (688293.SH) has announced a plan to acquire 100% equity of Pengli Bio through a combination of issuing shares and cash payment, while also raising supporting funds [1][2][3] Group 1: Transaction Details - The transaction price for acquiring Pengli Bio is set at 145,050.07 million yuan, with an assessed value of 145,200.00 million yuan, reflecting an increase of 52,494.42 million yuan and a valuation increase rate of 56.62% [2] - Aopu Mai plans to raise 73,000.00 million yuan in supporting funds to cover cash payments, taxes, and intermediary fees related to the transaction [3] - The issuance price for the new shares will not be less than 80% of the average trading price over the 20 trading days prior to the pricing date [3] Group 2: Shareholder Structure and Control - Prior to the transaction, there are no related party relationships between the transaction parties and the listed company, and the transaction will not change the control of the company [4] - As of March 31, 2025, the controlling shareholders are Xiao Zhihua and He Yunfen, holding a combined 32.06% of the company's shares [4] Group 3: Historical Financials - Aopu Mai's initial public offering raised a total of 164,370.56 million yuan, with a net amount of 151,094.48 million yuan after deducting issuance costs [5] - The company originally planned to raise 50,266.54 million yuan for various projects, including a CDMO biopharmaceutical production platform and a cell culture R&D center [5]